AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 211 min read

Wedbush maintains Outperform rating on Arcus Biosciences, $49 price target

Wedbush kept its Outperform rating on Arcus Biosciences (RCUS) with a $49 target, implying 106.3% upside. Analysts cite strong data for casdatifan, including 35-month mOS and 13-month mPFS, and promising combo therapy results with cabozantinib.

Original reporting
tradingview.com
Published Oct 21, 2026, 12:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 1:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Wedbush maintains Outperform rating on Arcus Biosciences, $49 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

Med
01

Why it matters

The upgrade and $49 target imply a 106% upside from the recent close, indicating a strong short‑term catalyst.

02

Market read

Analyst upgrade driven by new trial data could prompt buying interest in ARCX and related oncology stocks.

03

What to watch

Potential competition from other late‑line therapies and the need for larger confirmatory trials.

Relevance 8/10Novelty 8/10Timing: today

Background

Arcus Biosciences (NASDAQ: ARCX) is a clinical‑stage biotech focused on oncology. The analyst note highlights new data for its lead asset casdatifan and a combination with cabozantinib.

Market effects

Sector

Positive data may lift peer biotech stocks in the oncology space.

Regional

U.S. biotech sector could see modest gains.

Global

Limited to investors tracking oncology pipeline developments.

Counterpoint

What could challenge this read

Skeptics may question the durability of the trial results and the path to regulatory approval.

Key entities

  • company
    Arcus Biosciences

    Biotech firm developing casdatifan for late‑line cancer therapy.

  • analyst_firm
    Wedbush

    Equity research firm that issued the Outperform rating.

Read at source← All news

StoryArcus Biosciences presents ARC‑20 data showing strong efficacy of casdatifan across kidney‑cancer lines

Also covered by

1 outlet

Related articles

OCT 21
$RCUSMedAI 8/10

Arcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor Day

Arcus Biosciences (RCUS) presented data on casdatifan at its Investor Day, highlighting a $5B-$10B opportunity in renal cell carcinoma (RCC). The company reported promising results from Phase III trials, including a median progression-free survival of 14.5 months for the casdatifan-cabozantinib combination. Arcus plans to begin a first-line trial, PEAK-20, by year-end, with progression-free survival as the primary endpoint.

finance.yahoo.com2 min
OCT 20
$RCUSHighAI 9/10

Biotech Stocks Make NYSE Top Gainers October 20th

Arcus Biosciences (NYSE: RCUS) shares rose 9.53% to $24.25 after presenting positive data for its cancer treatment, casdatifan, across various kidney cancer settings. The company reported progression-free survival exceeding benchmarks in first- and second-line treatments, and a nearly three-year median overall survival in late-line settings. Arcus plans to initiate a registrational trial for casdatifan plus tivozanib by year-end.

investorideas.com3 min